Content Status
Type
Linked Node
Root cause analysis for low performance in in Percentage of Rifampicin-resistant (RR)/ Multidrug-resistant (MDR)-TB Cases Initiated on Treatment out of the Total Diagnosed
Learning ObjectivesRCA for Low Performance in Percentage of Rifampicin-resistant (RR)/ Multidrug-resistant (MDR)-TB Cases Initiated on Treatment out of the Total Diagnosed
Root Cause Analysis of Low Performance in Percentage of Rifampicin-resistant (RR)/ Multidrug-resistant (MDR)-TB Cases Initiated on Treatment out of the Total Diagnosed
Low performance means the diagnosed cases of MDR/ RR-TB cases are not started on treatment as desired.
Obtain the data from the Programmatic Management of Drug-resistant TB (PMDT) quarterly report and Ni-kshay and analyse in terms of:
- Who was not initiated on treatment? (Person Analysis) - Patients from the public sector or private sector, of any specific age group (elderly or paediatric), of any specific gender.
- Whether the problem is more in a specific geography? (Place Analysis) - Patients from a particular TB Unit (TU)/ Peripheral Health Institute (PHI)? Patients staying in specific geographical areas (difficult to access areas).
Once this is done, analyse at the process level. The process is:
- Patient diagnosed as RR/ MDR-TB in the lab and data entered in Ni-kshay
- Patient should be traced (at PHI/ private hospital) and information disclosed
- Pretreatment evaluation
- Initiation of treatment
Case to case audit can be done to find the cause against each patient.
Discussion with patients, treatment supporters and verification of source records may be done to get more information.
Examine if there is a pattern - e.g., only patients from one particular place (may be hard to reach area) are not initiated on treatment.
There may not be a single pattern. Then examine the most common patterns.
Understanding the underlying cause is important to address the problem in an efficient manner.
Possible Causes | Suggested Solutions | |
Is there any problem in patient tracing and contact at PHI/ private hospital level? |
|
|
Patient resistance |
|
|
Is there any issue in pretreatment evaluation? |
|
|
Is there a delay in the initiation of treatment? |
|
|
Do the patients from the private sector have issues in starting treatment? |
|
|
Other causes |
|
|
Note: This page describes only an approach for analysis of low performance and has not captured the entire list of problems or solutions. The root cause analysis may be modified according to the local context.
Resources
- India TB Report, CTD, GoI, 2022.
- TB Training Modules (5-9) for Programme Managers and Medical Officers, NTEP, CTD, MoHFW, GoI, 2020.
- Guidelines for Programmatic Management of Drug-resistant Tuberculosis in India, NTEP, CTD, MoHFW, GoI, 2021.
Assessment
Question | Option1 | Option 2 | Option 3 | Option 4 | Correct answer | Explanation | Page id | Pretest | Post-test |
Which of the following does not minimise the delay in treatment initiation/ treatment not initiated for MDR-TB cases? | Timely tracing of the patient | Proper counselling of the patient | A trained treatment provider | Not offering drugs to private patients | 4 | Timely tracing of the patient. proper counselling of the patient, a trained treatment provider will help minimise the delay in treatment initiation. |
Content Creator
Reviewer
Target Audience
- Log in to post comments